<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.retrovirology.com/feeds/mostaccessed/journal?quantity=&amp;format=rss&amp;version=">
        <title>Retrovirology - Most accessed articles</title>
        <link>http://www.retrovirology.com</link>
        <description>The most accessed research articles published by Retrovirology</description>
        <dc:date>2012-01-27T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.retrovirology.com/content/9/1/5" />
                                <rdf:li rdf:resource="http://www.retrovirology.com/content/9/1/6" />
                                <rdf:li rdf:resource="http://www.retrovirology.com/content/3/1/67" />
                                <rdf:li rdf:resource="http://www.retrovirology.com/content/9/1/3" />
                                <rdf:li rdf:resource="http://www.retrovirology.com/content/8/1/102" />
                                <rdf:li rdf:resource="http://www.retrovirology.com/content/9/1/10" />
                                <rdf:li rdf:resource="http://www.retrovirology.com/content/6/1/107" />
                                <rdf:li rdf:resource="http://www.retrovirology.com/content/9/1/7" />
                                <rdf:li rdf:resource="http://www.retrovirology.com/content/9/1/4" />
                                <rdf:li rdf:resource="http://www.retrovirology.com/content/3/1/68" />
                            </rdf:Seq>
        </items>
                 <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.retrovirology.com/content/9/1/5">
        <title>Relationships of PBMC microRNA expression, plasma viral load, and CD4+ T-cell count in HIV-1-infected elite suppressors and viremic patients</title>
        <description>Background:
HIV-1-infected elite controllers or suppressors (ES) maintain undetectable viral loads (&lt;50 copies/mL) without antiretroviral therapy. The mechanisms of suppression are incompletely understood. Modulation of HIV-1 replication by miRNAs has been reported, but the role of small RNAs in ES is unknown. Using samples from a well-characterized ES cohort, untreated viremic patients, and uninfected controls, we explored the PBMC miRNA profile and probed the relationships of miRNA expression, CD4+ T-cell counts, and viral load.
Results:
miRNA profiles, obtained using multiple acquisition, data processing, and analysis methods, distinguished ES and uninfected controls from viremic HIV-1-infected patients. For several miRNAs, however, ES and viremic patients shared similar expression patterns. Differentially expressed miRNAs included those with reported roles in HIV-1 latency (miR-29 family members, miRs -125b and -150). Others, such as miR-31 and miR-31*, had no previously reported connection with HIV-1 infection but were found here to differ significantly with uncontrolled HIV-1 replication. Correlations of miRNA expression with CD4+ T-cell count and viral load were found, and we observed that ES with low CD4+ T-cell counts had miRNA profiles more closely related to viremic patients than controls. However, expression patterns indicate that miRNA variability cannot be explained solely by CD4 variation.
Conclusions:
The intimate involvement of miRNAs in disease processes is underscored by connections of miRNA expression with the HIV disease clinical parameters of CD4 count and plasma viral load. However, miRNA profile changes are not explained completely by these variables. Significant declines of miRs-125b and -150, among others, in both ES and viremic patients indicate the persistence of host miRNA responses or ongoing effects of infection despite viral suppression by ES. We found no negative correlations with viral load in viremic patients, not even those that have been reported to silence HIV-1 in vitro, suggesting that the effects of these miRNAs are exerted in a focused, cell-type-specific manner. Finally, the observation that some ES with low CD4 counts were consistently related to viremic patients suggests that miRNAs may serve as biomarkers for risk of disease progression even in the presence of viral suppression.</description>
        <link>http://www.retrovirology.com/content/9/1/5</link>
                <dc:creator>Kenneth Witwer</dc:creator>
                <dc:creator>Andria Watson</dc:creator>
                <dc:creator>Joel Blankson</dc:creator>
                <dc:creator>Janice Clements</dc:creator>
                <dc:source>Retrovirology 2012, null:5</dc:source>
        <dc:date>2012-01-12T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4690-9-5</dc:identifier>
                            <dc:title>MicroRNA plays key role in HIV suppression</dc:title>
                            <dc:description>miRNA profiles, obtained using multiple acquisition, data processing, and analysis methods, distinguished ES and uninfected controls from viremic HIV-1-infected patients. For several miRNAs, however, ES and viremic patients shared similar expression patterns. Differentially expressed miRNAs included those with reported roles in HIV-1 latency (miR-29 family members, miRs -125b and -150). Others, such as miR-31 and miR-31*, had no previously reported connection with HIV-1 infection but were found here to differ significantly with uncontrolled HIV-1 replication.</dc:description>
                <prism:require>/content/figures/1742-4690-9-5-toc.gif</prism:require>
                <prism:publicationName>Retrovirology</prism:publicationName>
        <prism:issn>1742-4690</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>5</prism:startingPage>
        <prism:publicationDate>2012-01-12T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.retrovirology.com/content/9/1/6">
        <title>HIV infection and HERV expression: a review</title>
        <description>The human genome contains multiple copies of retrovirus genomes known as endogenous retroviruses (ERVs) that have entered the germ-line at some point in evolution. Several of these proviruses have retained (partial) coding capacity, so that a number of viral proteins or even virus particles are expressed under various conditions. Human ERVs (HERVs) belong to the beta-, gamma-, or spuma- retrovirus groups. Endogenous delta- and lenti- viruses are notably absent in humans, although endogenous lentivirus genomes have been found in lower primates. Exogenous retroviruses that currently form a health threat to humans intriguingly belong to those absent groups. The best studied of the two infectious human retroviruses is the lentivirus human immunodeficiency virus (HIV) which has an overwhelming influence on its host by infecting cells of the immune system. One HIV-induced change is the induction of HERV transcription, often leading to induced HERV protein expression. This review will discuss the potential HIV-HERV interactions.Several studies have suggested that HERV proteins are unlikely to complement defective HIV virions, nor is HIV able to package HERV transcripts, probably due to low levels of sequence similarity. It is unclear whether the expression of HERVs has a negative, neutral, or positive influence on HIV-AIDS disease progression. A positive effect was recently reported by the specific expression of HERVs in chronically HIV-infected patients, which results in the presentation of HERV-derived peptides to CD8+ T-cells. These cytotoxic T-cells were not tolerant to HERV peptides, as would be expected for self-antigens, and consequently lysed the HIV-infected, HERV-presenting cells. This novel mechanism could control HIV replication and result in a low plasma viral load. The possibility of developing a vaccination strategy based on these HERV peptides will be discussed.</description>
        <link>http://www.retrovirology.com/content/9/1/6</link>
                <dc:creator>Antoinette van der Kuyl</dc:creator>
                <dc:source>Retrovirology 2012, null:6</dc:source>
        <dc:date>2012-01-16T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4690-9-6</dc:identifier>
                                    <dc:description>The human genome contains multiple copies of retrovirus genomes known as endogenous retroviruses (ERVs) that have entered the germ-line at some point in evolution. This review discusses how HIV-1 infection influences the expression of HERVs.</dc:description>
                <prism:require>/content/figures/1742-4690-9-6-toc.gif</prism:require>
                <prism:publicationName>Retrovirology</prism:publicationName>
        <prism:issn>1742-4690</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>6</prism:startingPage>
        <prism:publicationDate>2012-01-16T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.retrovirology.com/content/3/1/67">
        <title>The discovery of endogenous retroviruses</title>
        <description>When endogenous retroviruses (ERV) were discovered in the late 1960s, the Mendelian inheritance of retroviral genomes by their hosts was an entirely new concept. Indeed Howard M Temin&apos;s DNA provirus hypothesis enunciated in 1964 was not generally accepted, and reverse transcriptase was yet to be discovered. Nonetheless, the evidence that we accrued in the pre-molecular era has stood the test of time, and our hypothesis on ERV, which one reviewer described as &apos;impossible&apos;, proved to be correct. Here I recount some of the key observations in birds and mammals that led to the discovery of ERV, and comment on their evolution, cross-species dispersion, and what remains to be elucidated.</description>
        <link>http://www.retrovirology.com/content/3/1/67</link>
                <dc:creator>Robin Weiss</dc:creator>
                <dc:source>Retrovirology 2006, null:67</dc:source>
        <dc:date>2006-10-03T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4690-3-67</dc:identifier>
                                <prism:require>/content/figures/1742-4690-3-67-toc.gif</prism:require>
                <prism:publicationName>Retrovirology</prism:publicationName>
        <prism:issn>1742-4690</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>67</prism:startingPage>
        <prism:publicationDate>2006-10-03T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.retrovirology.com/content/9/1/3">
        <title>Host cell species-specific effect of cyclosporine A on simian immunodeficiency virus replication</title>
        <description>Background:
An understanding of host cell factors that affect viral replication contributes to elucidation of the mechanism for determination of viral tropism. Cyclophilin A (CypA), a peptidyl-prolyl cis-trans isomerase (PPIase), is a host factor essential for efficient replication of human immunodeficiency virus type 1 (HIV-1) in human cells. However, the role of cyclophilins in simian immunodeficiency virus (SIV) replication has not been determined. In the present study, we examined the effect of cyclosporine A (CsA), a PPIase inhibitor, on SIV replication.
Results:
SIV replication in human CEM-SS T cells was not inhibited but rather enhanced by treatment with CsA, which inhibited HIV-1 replication. CsA treatment of target human cells enhanced an early step of SIV replication. CypA overexpression enhanced the early phase of HIV-1 but not SIV replication, while CypA knock-down resulted in suppression of HIV-1 but not SIV replication in CEM-SS cells, partially explaining different sensitivities of HIV-1 and SIV replication to CsA treatment. In contrast, CsA treatment inhibited SIV replication in macaque T cells; CsA treatment of either virus producer or target cells resulted in suppression of SIV replication. SIV infection was enhanced by CypA overexpression in macaque target cells.
Conclusions:
CsA treatment enhanced SIV replication in human T cells but abrogated SIV replication in macaque T cells, implying a host cell species-specific effect of CsA on SIV replication. Further analyses indicated a positive effect of CypA on SIV infection into macaque but not into human T cells. These results suggest possible contribution of CypA to the determination of SIV tropism.</description>
        <link>http://www.retrovirology.com/content/9/1/3</link>
                <dc:creator>Hiroaki Takeuchi</dc:creator>
                <dc:creator>Hiroshi Ishii</dc:creator>
                <dc:creator>Tetsuya Kuwano</dc:creator>
                <dc:creator>Natsuko Inagaki</dc:creator>
                <dc:creator>Hirofumi Akari</dc:creator>
                <dc:creator>Tetsuro Matano</dc:creator>
                <dc:source>Retrovirology 2012, null:3</dc:source>
        <dc:date>2012-01-06T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4690-9-3</dc:identifier>
                                    <dc:description>This paper shows that CsA treatment enhanced SIV replication in human T cells but abrogated SIV replication in macaque T cells, implying a host cell species-specific effect of CsA on SIV replication. Further analyses indicated a positive effect of CypA on SIV infection into macaque but not into human T cells. These results suggest possible contribution of CypA to the determination of SIV tropism.</dc:description>
                <prism:require>/content/figures/1742-4690-9-3-toc.gif</prism:require>
                <prism:publicationName>Retrovirology</prism:publicationName>
        <prism:issn>1742-4690</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>3</prism:startingPage>
        <prism:publicationDate>2012-01-06T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.retrovirology.com/content/8/1/102">
        <title>The 2011 Retrovirology Prize winner Masao Matsuoka: forward looking and antisense </title>
        <description>Masao Matsuoka wins the 2011 Retrovirology Prize.</description>
        <link>http://www.retrovirology.com/content/8/1/102</link>
                <dc:creator>Kuan-Teh Jeang</dc:creator>
                <dc:source>Retrovirology 2011, null:102</dc:source>
        <dc:date>2011-12-15T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4690-8-102</dc:identifier>
                                    <dc:description>Masao Matsuoka wins the 2011 Retrovirology Prize</dc:description>
                <prism:require>/content/figures/1742-4690-8-102-toc.gif</prism:require>
                <prism:publicationName>Retrovirology</prism:publicationName>
        <prism:issn>1742-4690</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>102</prism:startingPage>
        <prism:publicationDate>2011-12-15T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.retrovirology.com/content/9/1/10">
        <title>Bone marrow stromal cell antigen 2 (BST-2) restricts mouse mammary tumor virus (MMTV) replication in vivo</title>
        <description>Background:
Bone marrow stromal cell antigen 2 (BST-2) is a cellular factor that restricts the egress of viruses such as human immunodeficiency virus (HIV-1) from the surface of infected cells, preventing infection of new cells. BST-2 is variably expressed in most cell types and its expression is enhanced by cytokines such as type I interferon alpha (IFN-alpha). In this present study, we used the beta-retrovirus, mouse mammary tumor virus (MMTV) as a model to examine the role of mouse BST-2 in host infection in vivo.
Results:
By using RNA interference, we show that loss of BST-2 enhances MMTV replication in cultured mammary tumor cells and in vivo. In cultured cells, BST-2 inhibits virus accumulation in the culture medium, and co-localizes at the cell surface with virus structural proteins.   Furthermore, both scanning electron micrograph (SEM) and Transmission electron micrograph (TEM) show that MMTV accumulates on the surface of IFN alpha-stimulated cells.
Conclusions:
Our data provide evidence that BST-2 restricts MMTV release from naturally infected cells and that BST-2 is an antiviral factor in vivo.Running Title:  BST-2 restriction of virus replication in vivoKeywordsBST-2, Tetherin, Interferon alpha, MMTV, In vivo, SEM, TEM</description>
        <link>http://www.retrovirology.com/content/9/1/10</link>
                <dc:creator>Philip Jones</dc:creator>
                <dc:creator>Harshini Mehta</dc:creator>
                <dc:creator>Martina Maric</dc:creator>
                <dc:creator>Richard Roller</dc:creator>
                <dc:creator>Chioma Okeoma</dc:creator>
                <dc:source>Retrovirology 2012, null:10</dc:source>
        <dc:date>2012-01-27T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4690-9-10</dc:identifier>
                                    <dc:description>The findings in this work show that BST-2 restricts MMTV release from naturally infected cells and that BST-2 is an antiviral factor in vivo.</dc:description>
                <prism:require>/content/figures/1742-4690-9-10-toc.gif</prism:require>
                <prism:publicationName>Retrovirology</prism:publicationName>
        <prism:issn>1742-4690</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>10</prism:startingPage>
        <prism:publicationDate>2012-01-27T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.retrovirology.com/content/6/1/107">
        <title>Identification of an endogenous retroviral envelope gene with fusogenic activity and placenta-specific expression in the rabbit : a new &quot;syncytin&quot; in a third order of mammals

</title>
        <description>Background:
Syncytins are envelope genes of retroviral origin that have been co-opted by the host to mediate a specialized function in placentation. Two of these genes have already been identified in primates, as well as two distinct, non orthologous genes in rodents.
Results:
Here we identified within the rabbit Oryctolagus cuniculus-which belongs to the lagomorpha order- an envelope (env) gene of retroviral origin with the characteristic features of a bona fide syncytin, that we named syncytin-Ory1. An in silico search for full-length env genes with an uninterrupted open reading frame within the rabbit genome first identified two candidate genes that were tested for their specific expression in the placenta by quantitative RT-PCR of RNA isolated from a large set of tissues. This resulted in the identification of an env gene with placenta-specific expression and belonging to a family of endogenous retroelements present at a limited copy number in the rabbit genome. Functional characterization of the identified placenta-expressed env gene after cloning in a CMV-driven expression vector and transient transfection experiments, demonstrated both fusogenic activity in an ex vivo cell-cell fusion assay and infectivity of pseudotypes. The receptor for the rabbit syncytin-Ory1 was found to be the same as that for human syncytin-1, i.e. the previously identified ASCT2 transporter. This was demonstrated by a co-culture fusion assay between hamster A23 cells transduced with an expression vector for ASCT2 and A23 cells transduced with syncytin-Ory1. Finally, in situ hybridization of rabbit placenta sections with a syncytin-Ory1 probe revealed specific expression at the level of the junctional zone between the placental lobe and the maternal decidua, where the invading syncytial fetal tissue contacts the maternal decidua to form the labyrinth, consistent with a role in the formation of the syncytiotrophoblast. The syncytin-Ory1 gene is found in Leporidae but not in Ochotonidae, and should therefore have entered the lagomorpha order 12-30 million years ago.
Conclusion:
The identification of a novel syncytin gene within a third order of mammals displaying syncytiotrophoblast formation during placentation strongly supports the notion that on several occasions retroviral infections have resulted in the independent capture of genes that have been positively selected for a convergent physiological role.</description>
        <link>http://www.retrovirology.com/content/6/1/107</link>
                <dc:creator>Odile Heidmann</dc:creator>
                <dc:creator>Cecile Vernochet</dc:creator>
                <dc:creator>Anne Dupressoir</dc:creator>
                <dc:creator>Thierry Heidmann</dc:creator>
                <dc:source>Retrovirology 2009, null:107</dc:source>
        <dc:date>2009-11-27T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4690-6-107</dc:identifier>
                                <prism:require>/content/figures/1742-4690-6-107-toc.gif</prism:require>
                <prism:publicationName>Retrovirology</prism:publicationName>
        <prism:issn>1742-4690</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>107</prism:startingPage>
        <prism:publicationDate>2009-11-27T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.retrovirology.com/content/9/1/7">
        <title>Human immunodeficiency virus type 1 envelope proteins traffic toward virion assembly sites via a TBC1D20/Rab1-regulated pathway</title>
        <description>Background:
The cellular activity of many factors and pathways is required to execute the complex replication cycle of the human immunodeficiency virus type 1 (HIV-1). To reveal these cellular components, several extensive RNAi screens have been performed, listing numerous &apos;HIV-dependency factors&apos;. However, only a small overlap between these lists exists, calling for further evaluation of the relevance of specific factors to HIV-1 replication and for the identification of additional cellular candidates. TBC1D20, the GTPase-activating protein (GAP) of Rab1, regulates endoplasmic reticulum (ER) to Golgi trafficking, was not identified in any of these screens, and its involvement in HIV-1 replication cycle is tested here.FindingsExcessive TBC1D20 activity perturbs the early trafficking of HIV-1 envelope protein through the secretory pathway. Overexpression of TBC1D20 hampered envelope processing and reduced its association with detergent-resistant membranes, entailing a reduction in infectivity of HIV-1 virion like particles (VLPs).
Conclusions:
These findings add TBC1D20 to the network of host factors regulating HIV replication cycle.</description>
        <link>http://www.retrovirology.com/content/9/1/7</link>
                <dc:creator>Dikla Nachmias</dc:creator>
                <dc:creator>Ella Sklan</dc:creator>
                <dc:creator>Marcelo Ehrlich</dc:creator>
                <dc:creator>Eran Bacharach</dc:creator>
                <dc:source>Retrovirology 2012, null:7</dc:source>
        <dc:date>2012-01-19T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4690-9-7</dc:identifier>
                                    <dc:description>Excessive TBC1D20 activity perturbs the early trafficking of HIV-1 envelope protein through the secretory pathway. Overexpression of TBC1D20 hampered envelope processing and reduced its association with detergent-resistant membranes, entailing a reduction in infectivity of HIV-1 virion like particles (VLPs).</dc:description>
                <prism:require>/content/figures/1742-4690-9-7-toc.gif</prism:require>
                <prism:publicationName>Retrovirology</prism:publicationName>
        <prism:issn>1742-4690</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>7</prism:startingPage>
        <prism:publicationDate>2012-01-19T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.retrovirology.com/content/9/1/4">
        <title>Interactions between prostaglandins, leukotrienes and HIV-1:
possible implications for the central nervous system
</title>
        <description>In HIV-1-infected individuals, there is often discordance between viremia in peripheral blood and viral load found in the central nervous system (CNS). Although the viral burden is often lower in the CNS compartment than in the plasma, neuroinflammation is present in most infected individuals, albeit attenuated by the current combined antiretroviral therapy. The HIV-1-associated neurological complications are thought to result not only from direct viral replication, but also from the subsequent neuroinflammatory processes. The eicosanoids - prostanoids and leukotrienes - are known as potent inflammatory lipid mediators. They are often present in neuroinflammatory diseases, notably HIV-1 infection. Their exact modulatory role in HIV-1 infection is, however, still poorly understood, especially in the CNS compartment. Nonetheless, a handful of studies have provided evidence as to how these lipid mediators can modulate HIV-1 infection. This review summarizes findings indicating how eicosanoids may influence the progression of neuroAIDS.</description>
        <link>http://www.retrovirology.com/content/9/1/4</link>
                <dc:creator>Jonathan Bertin</dc:creator>
                <dc:creator>Corinne Barat</dc:creator>
                <dc:creator>Sylvie Methot</dc:creator>
                <dc:creator>Michel Tremblay</dc:creator>
                <dc:source>Retrovirology 2012, null:4</dc:source>
        <dc:date>2012-01-11T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4690-9-4</dc:identifier>
                                    <dc:description>The eicosanoids - prostanoids and leukotrienes - are known as potent inflammatory lipid mediators. They are often present in neuroinflammatory diseases, notably HIV-1 infection. Their exact modulatory role in HIV-1 infection is however still poorly understood, especially in the CNS compartment. Nonetheless, a handful of studies have provided evidence as to how these lipid mediators can modulate HIV-1 infection. This review summarizes findings indicating how eicosanoids may influence the progression of neuroAIDS.</dc:description>
                <prism:require>/content/figures/1742-4690-9-4-toc.gif</prism:require>
                <prism:publicationName>Retrovirology</prism:publicationName>
        <prism:issn>1742-4690</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>4</prism:startingPage>
        <prism:publicationDate>2012-01-11T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.retrovirology.com/content/3/1/68">
        <title>Host-virus interaction: a new role for microRNAs</title>
        <description>MicroRNAs (miRNAs) are a new class of 18&#8211;23 nucleotide long non-coding RNAs that play critical roles in a wide spectrum of biological processes. Recent reports also throw light into the role of microRNAs as critical effectors in the intricate host-pathogen interaction networks. Evidence suggests that both virus and hosts encode microRNAs. The exclusive dependence of viruses on the host cellular machinery for their propagation and survival also make them highly susceptible to the vagaries of the cellular environment like small RNA mediated interference. It also gives the virus an opportunity to fight and/or modulate the host to suite its needs. Thus the range of interactions possible through miRNA-mRNA cross-talk at the host-pathogen interface is large. These interactions can be further fine-tuned in the host by changes in gene expression, mutations and polymorphisms. In the pathogen, the high rate of mutations adds to the complexity of the interaction network. Though evidence regarding microRNA mediated cross-talk in viral infections is just emerging, it offers an immense opportunity not only to understand the intricacies of host-pathogen interactions, and possible explanations to viral tropism, latency and oncogenesis, but also to develop novel biomarkers and therapeutics.</description>
        <link>http://www.retrovirology.com/content/3/1/68</link>
                <dc:creator>Vinod Scaria</dc:creator>
                <dc:creator>Manoj Hariharan</dc:creator>
                <dc:creator>Souvik Maiti</dc:creator>
                <dc:creator>Beena Pillai</dc:creator>
                <dc:creator>Samir Brahmachari</dc:creator>
                <dc:source>Retrovirology 2006, null:68</dc:source>
        <dc:date>2006-10-11T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4690-3-68</dc:identifier>
                                <prism:require>/content/figures/1742-4690-3-68-toc.gif</prism:require>
                <prism:publicationName>Retrovirology</prism:publicationName>
        <prism:issn>1742-4690</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>68</prism:startingPage>
        <prism:publicationDate>2006-10-11T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>

